Thermo Fisher Scientific has announced a new portfolio of research-use-only hematology-oncology assays for its Ion Torrent Genexus System, with the firm's Oncomine Myeloid Assay GX being launched as the initial assay in the series.
The new panel allows simultaneous analysis of DNA mutations and RNA fusion transcripts in myeloid samples in a single day. It also provides the ability to profile 40 DNA targets and 29 fusion driver genes, allowing users to detect more than 600 fusion isotypes to identify biomarkers associated with myeloproliferative neoplasm, acute myeloid leukemia (AML), and myelodysplastic syndrome. The firm said that the assay maximizes detection of relevant biomarkers, including TP53, CEBPA, NPM1, RUNX1, PML-RARA, IDH 1, IDH 2, and FLT3-ITD, which is a common driver mutation associated with poor prognosis in AML.
Thermo Fisher intends to follow up the Myeloid Assay GX with additional hematology-oncology clinical research assays for B-cell and T-cell clonality and somatic hypermutation assessment through immune repertoire sequencing to study lymphoid malignancies, including chronic lymphocytic leukemia, acute lymphoblastic leukemia, multiple myeloma, as well as Hodgkin's and non-Hodgkin's lymphomas. The firm also plans to launch a lymphoid gene panel covering a comprehensive set of targets relevant for a range of lymphoid neoplasms. All assays will be available for the Genexus System.